Generation of New Drugs for Neglected Tropical Diseases

Sanofi and DNDi - Drugs for Neglected Diseases initiative - Sign an Innovative Agreement to Generate New Drugs for Neglected Tropical Diseases. Sanofi and Drugs for Neglected Diseases initiative announced a three-year research collaboration agreement for the research of new treatments for nine neglected tropical diseases (NTDs), listed by the World Health Organization (WHO) for which new, adapted, and efficient tools are urgently needed to treat patients in endemic countries. This agreement is built upon a history of successful collaboration between Sanofi and DNDi.

In the framework of this agreement, Sanofi will initially bring molecules from its libraries into the partnership, while DNDi and Sanofi collaborate in research activities on innovative molecular scaffolds. The core of the agreement lies in the innovative management of intellectual property generated through the collaboration. The rights to results produced by this partnership will be co- owned by Sanofi and DNDi. The partners will facilitate publication of the results to ensure access to the wider community of researchers focusing on NTDs. The public sector will benefit from the drugs developed through this agreement under the best possible conditions to ease access for patients in all endemic countries, irrespective of their level of economic development.

Neglected Tropical Diseases covered by the agreement

This agreement covers nine neglected tropical diseases (NTDs): kinetoplastid diseases (leishmaniases, Chagas disease, and human African trypanosomiasis), helminth infections (lymphatic filariasis, onchocerciasis, and soil-transmitted helminthiasis), and dracunculiasis, fascioliasis, and schistosomiasis.

[Press Release]